India - a biotech growth catalyst
India is among the top 12 destinations for biotechnology in the world, with approximately 3% share in the global Biotechnology industry. India is also the leader in the global supply of DPT, BCG and measles vaccines.
The biotechnology industry in India comprises about 600+ core biotechnology companies, approximately 2600+ biotech startups, 50 BIRAC-supported incubators.
India has the second-highest number of US Food & Drug Administration (USFDA)-approved manufacturing plants outside the US and over 1,300 manufacturing plants compliant with World Health Organisation (WHO) Good Manufacturing Practices.
- By 2025, the Indian Biotechnology industry is expected to reach $100 bn
- By 2025, the contribution of the Indian biotechnology industry in the global biotechnology market is expected to grow to 19% from 3% in 2017
100% FDI is allowed under the automatic route for greenfield pharma.
100% FDI is allowed under the government route for brownfield pharma in upto 74% FDI is under automatic route and beyond 74% is under the government approval route.
FDI up to 100% is allowed under the automatic route for the manufacturing of medical devices.
For further details, please refer FDI Policy